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Aberrant cell-cycle activity and DNA damage are
emerging as important pathological components in
various neurodegenerative conditions. However,
their underlying mechanisms are poorly understood.
Here, we show that deregulation of histone deacety-
lase 1 (HDAC1) activity byp25/Cdk5 induces aberrant
cell-cycle activity and double-strand DNA breaks
leading to neurotoxicity. In a transgenic model for
neurodegeneration, p25/Cdk5 activity elicited cell-
cycle activity and double-strand DNA breaks that
preceded neuronal death. Inhibition of HDAC1 activ-
ity by p25/Cdk5 was identified as an underlying
mechanism for these events, and HDAC1 gain of
function provided potent protection against DNA
damage and neurotoxicity in cultured neurons and
an in vivo model for ischemia. Our findings outline
a pathological signaling pathway illustrating the im-
portance of maintaining HDAC1 activity in the adult
neuron. This pathway constitutes amolecular link be-
tween aberrant cell-cycle activity and DNA damage
and is a potential target for therapeutics against dis-
eases and conditions involving neuronal death.
INTRODUCTION
In a variety of conditions involving neuronal death such as ische-
mia and Alzheimer’s disease (Hayashi et al., 2000; Rashidian
et al., 2007; Vincent et al., 1996; Yang et al., 2001), neurons
engage in aberrant cell-cycle activities, expressing cell-cycle
markers such as Ki-67 and proliferating cell nuclear antigen
(PCNA) and synthesizing DNA (Yang et al., 2001). This is remark-
able considering that neurons are terminally differentiated and
remain quiescent for decades prior to the onset of these events.
While the underlying mechanisms are poorly understood, these
activities may play an early and contributory role in neuronal death
(Busser et al., 1998; Herrup and Busser, 1995). For example,
overexpression of cell-cycle activity-inducing proteins such as
SV40 large T antigen, c-Myc, c-Myb, or E2F1 can cause neuronaldeath in vitro and in vivo (al-Ubaidi et al., 1992; Konishi and Bonni,
2003; Liu and Greene, 2001), while pharmacological inhibitors of
cyclin-dependent kinases (CDKs) or other cell-cycle components
can exert neuroprotective effects (Padmanabhan et al., 1999).
DNA damage may also be involved in numerous conditions
involving neuronal death (Adamec et al., 1999; Ferrante et al.,
1997; Hayashi et al., 1999; Kruman et al., 2004; Robison and
Bradley, 1984). For example, oxidative damage to neuronal
DNA is observed in rodent models of ischemia (Hayashi et al.,
1999). Accumulation of reactive oxygen species results in DNA
damage, cell-cycle activity, and neurodegeneration in mutant
mice with disrupted apoptosis-inducing factor (AIF) (Klein
et al., 2002). In addition, congenital syndromes with DNA repair
gene mutations, such as ataxia telangiectasia and Werner’s syn-
drome, display a progressive neurodegeneration phenotype,
demonstrating the importance of maintaining DNA integrity in
the adult brain (Rolig and McKinnon, 2000). DNA damage is in-
volved in the aging of the human brain (Lu et al., 2004), which
suggests that DNA damage may play a role in age-dependent
neurodegenerative diseases as well.
Regulating histone acetylation is an integral aspect of chroma-
tin modulation and gene regulation that plays a critical role in
many biological processes including cell proliferation and differ-
entiation (Roth et al., 2001). Recent reports have detailed the
importance of histone acetylation in central nervous system
(CNS) functions such as neuronal differentiation, memory forma-
tion, drug addiction, and depression (Citrome, 2003; Tsankova
et al., 2006). Histone deacetylases (HDACs) remove acetyl
groups from histones, resulting in chromatin compaction and
decreased accessibility to DNA for interacting molecules such
as transcription factors (Cerna et al., 2006). Of these, histone de-
acetylase 1 (HDAC1) was the first mammalian protein identified
to have histone-directed deacetylase activity (Taunton et al.,
1996). HDAC1 plays important roles in regulating the cell cycle
and is required in the transcriptional repression of cell-cycle
genes such as p21/WAF, E2F1, and cyclins A and E (Brehm
et al., 1998; Lagger et al., 2002; Rayman et al., 2002; Stiegler
et al., 1998). The association of HDAC1 with promoter regions
of specific genes is linked to their transcriptional repression
(Brehm et al., 1998; Gui et al., 2004; Rayman et al., 2002).
The serine/threonine kinase Cdk5 and its activating subunit
p35 play important roles in both the developing and adult CNSNeuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc. 803
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including postmortem Alzheimer’s disease (AD) brains and ani-
mal models for stroke/ischemia (Lee et al., 2000; Nguyen et al.,
2001; Patrick et al., 1999; Smith et al., 2003; Swatton et al.,
2004; Wang et al., 2003), neurotoxic stimuli induce calpain-
mediated cleavage of p35 into p25, the accumulation of which
elicits neurotoxicity in cultured neurons and in vivo (Lee et al.,
2000; Patrick et al., 1999).
We have previously generated a bitransgenic mouse model
(CK-p25 mice) that expresses a p25-GFP fusion protein under
the control of the calmodulin kinase II (CaMKII) promoter in an
inducible, postdevelopmental, and forebrain-specific manner
(Cruz et al., 2003). Upon induction of p25, neurodegenerative
events occur in a rapid and orderly manner, as astrogliosis is
observed after 4 weeks of induction, and neuronal loss and
cognitive impairment are appreciable after 6 weeks of induction
(Cruz et al., 2003; Fischer et al., 2005). Thus, this model may
provide a tractable system for investigating mechanisms for neu-
ronal death relevant to conditions involving p25, such as stroke/
ischemia.
Here, we examined the gene expression profile in p25 trans-
genic mice induced for a short period to gain insights into early
and instigating mechanisms involved in neurodegeneration.
We observed that following p25 induction, neurons aberrantly
express cell-cycle proteins and form double-strand DNA breaks
at an early stage prior to their death. p25 interacted with and
inactivated HDAC1, and inactivation of HDAC1 through siRNA
knockdown or pharmacological inhibition resulted in double-
strand DNA breaks, aberrant cell-cycle protein expression, and
neuronal death. Importantly, restoring HDAC1 activity by overex-
pressing wild-type HDAC1, but not the deacetylase activity-
deficient mutant, rescued against p25-mediated double-strand
DNA breaks and cell death. Furthermore, we provide evidence
that this pathway is relevant in an in vivo model for stroke. Our
findings suggest that the inactivation of HDAC1 by p25 may be
involved in the pathogenesis of neurodegenerative diseases.
RESULTS
Gene Expression Profile of CK-p25 Transgenic Mice
In CK-p25 mice induced for 2 weeks, widespread forebrain
neuron-specific expression of p25-GFP is observed (see Fig-
ure S1 available online) without signs of neurotoxicity or reactive
astrogliosis (Fischer et al., 2005). We carried out microarray anal-
yses of CK-p25 mouse forebrains (Affymetrix; see Supplemental
Experimental Procedures) at this period of induction in hopes of
elucidating the initiating mechanisms accounting for the neuro-
degeneration observed in later weeks. A total of 225 genes (292
total probes) were found to be significantly altered in the induced
transgenics compared to uninduced controls (Table S1). Surpris-
ingly, genes involved in cell-cycle or DNA damage repair/
response (Gene Ontology database, http://www.geneontology.
org/) were highly represented (Table S2), totaling 65 genes
(84 total probes) with overlap between the annotation groups.
Representative genes from these groups are summarized in
Table 1. Of the 65 genes, 63 were upregulated, including cell-cy-
cle/proliferation genes such as cyclins A, B, and E, E2F1, Ki-67,
andPCNA, which have previously been shown to be upregulated
in postmortem AD brains and rodent stroke models. In addition,
a number of DNA damage response genes, in particular genes in-
volved in the double-strand DNA break response such asRad51,
BRCA1, and checkpoint 1 (Chk1), were found to be highly upre-
gulated. Collectively, these findings suggest the aberrant expres-
sion of cell-cycle proteins and a response to double-strand DNA
breaks in the brains of CK-p25 mice.
p25 Induction Results in Aberrant Expression
of Cell-Cycle Proteins
We examined the expression of various cell-cycle proteins in
CK-p25 mouse brains to confirm their aberrant upregulation as
suggested by the microarray analyses. We confirmed by semi-
quantitative RT-PCR that mRNA levels of various cell-cycle
genes identified in the microarray were upregulated in CK-p25
mouse hippocampi compared to wild-type (WT) controls (Fig-
ure 1A). In addition, protein levels of PCNA, E2F1, and cyclin A
were upregulated compared to WT controls (Figure 1B). There
was no change in levels of glial fibrillary acidic protein (GFAP),
consistent with the absence of neurodegeneration at this period
of induction. Immunostaining demonstrated robust increases in
immunoreactivity for the cell-cycle progression/proliferation
markers Ki-67 and PCNA in p25-expressing adult neurons,
which were identified by the GFP signal (Figures 1C and 1D).
Importantly, only neurons expressing p25-GFP were found to
have increased levels of cell-cycle markers, while no neurons
expressed these markers in WT mice. Some nonneuronal cells
stained positively for these cell-cycle markers (e.g., in the sub-
ventricular zone) in both CK-p25 and WT brains (data not shown),
reflecting normal cell-cycle activity in nonpostmitotic cells. In
addition, a subset of p25-GFP neurons incorporated bromo-
deoxyuridine (BrdU), indicating DNA synthesis activity (data not
shown). On the other hand, p25-GFP-expressing neurons were
not immunoreactive for the mitotic marker phosphoserine 10
histone H3, indicating the absence of mitotic cell-cycle activity
(Figure 1E). Our results imply that p25 induction results in aber-
rant expression of cell-cycle proteins in neurons and aberrant
cell-cycle activity.
p25 Induction Results in Double-Strand DNA Breaks
The microarray analyses also suggested that p25 expression
induced many genes involved in the double-strand DNA break
response. To determine whether double-strand DNA breaks
occur in CK-p25 mice, brains from 2-week-induced mice were
examined using the double-strand break marker phosphoserine
129 histone H2AX (gH2AX). Robust gH2AX immunoreactivity
was detected both biochemically (Figure 2A) and by staining,
revealing that gH2AX immunoreactivity was specific to p25-
GFP-expressing neurons (Figure 2B). gH2AX staining was unde-
tectable in WT brain neurons. The double-strand DNA break
response protein Rad51 was also found to be upregulated in
CK-p25 brains (Figure 2A).
We examined whether p25-mediated induction of double-
strand breaks could be recapitulated in cultured primary neurons
using herpes simplex virus (HSV)-mediated overexpression of
p25. Expression of p25 in primary neurons also resulted in robust
generation of gH2AX (Figures 2C and 2D). To provide physical
proof of DNA damage, primary neurons overexpressing p25804 Neuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc.
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trophoresis (comet assay). We observed that nuclei of p25-over-
expressing neurons displayed an 1.8-fold higher incidence of
comet tails indicative of DNA containing single- or double-strand
breaks (Figure 2E). These results demonstrate that expression of
p25 induces DNA strand breaks in neurons.
Table 1. Genes Involved in Cell-Cycle and DNA Damage Response Are Upregulated in the Forebrains of Induced CK-p25 Mice
Function Gene Name Accession Number Fold Change
Cell-Cycle-Related Genes Cyclin A2 X75483 3.78
Cyclin B1 NM_007629 10.58
Cyclin E1 NM_007633 1.94
Cyclin E2 AF091432 4.9
Cdc28 NM_016904 2.4
Cdc28 regulatory subunit 1 NM_025415 5.11
Cdc2a (cdk1) NM_007659 8.47
Cdc20 BB041150 4.09
Cell division associated 1 (Nuf2R) AK010351 2.16
Polo-like kinase 4 AI385771 2.9
Geminin NM_020567 2.27
Mcm2 NM_008564 5.01
Mcm3 C80350 6.27
Mcm4 BC013094 3.06
Mcm6 NM_008567 6.04
Mcm7 NM_008568 3.78
DNA primase, p49 subunit J04620 3.19
DNA primase, p58 subunit NM_008922 1.67
p21/WAF AK007630 2.55
Proliferating cell nuclear antigen (PCNA) BC010343 2.47
Ki-67 proliferation antigen X82786 16.14
E2F1 NM_007891 5.04
Transcription factor DP-1 BG075396 1.73
DNA Damage Response Genes Rad51 NM_011234 31.77
Rad51 associated protein BC003738 9.93
Topoisomerase II alpha BM211413 6.02
DNA methyltransferase (cytosine-5) 1 NM_010066 1.67
Flap endonuclease BB393998 2.65
MutS homolog 6 U42190 1.66
Ligase I NM_010715 3.99
DNA polymerase epsilon NM_011132 37.8
DNA polymerase delta 1, catalytic subunit BB385244 1.93
Pmaip1 NM_021451 5.23
Deoxyuridine triphosphatase AF091101 1.65
Ribonucleotide reductase M2 BB758819 5.65
Replication protein A1 BB491281 1.64
Replication protein A2 AK011530 2.13
Uracil DNA glycosylase BC004037 3.24
Chromatin assembly factor 1b NM_011132 5.81
BRCA1 U31625 5.45
Checkpoint 1 C85740 8.06
Mad2-like 1 NM_019499 2.59
Microarray analysis was carried out as described in Experimental Procedures, and genes were organized into functional groups based on gene
ontology. Genes with multiple gene ontology annotations (e.g., PCNA) were arbitrary placed into one of the groups. Fold change is measured in terms
of expression levels for p25 compared to controls at 2 weeks of induction. The entire list of genes with significantly altered expression (Table S1) and
cell-cycle/DNA damage-related genes (Table S2) are shown in the Supplemental Data.Neuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc. 805
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(A) Hippocampi from 2-week-induced CK-p25 mice and wild-type (WT) mice were subjected to total RNA extraction, reverse transcription, and semiquantitative
PCR analysis as described. Representative blots of mRNA levels of various cell-cycle genes from CK-p25 and WT hippocampi at 20, 25, and 30 cycles of
semiquantitative RT-PCR are shown at left. Quantifications from multiple animals are displayed in the histogram at right. Band quantifications were normalized
to actin levels. Data are displayed as average ± SEM fold increase over WT, with WT samples set to 1. p values (*p < 0.05) were calculated from multiple animals
by two-tailed, unpaired Student’s t test.
(B) Forebrains from 2-week-induced CK-p25 mice and WT controls were analyzed for PCNA, cyclin A, and E2F1 protein levels. Glial fibrillary acidic protein (GFAP)
and bIII-tubulin, used as loading control, were unchanged.
(C) Ki-67, a cell-cycle progression marker, was upregulated in p25-expressing neurons in CK-p25 brains (top panels), but not in neurons of WT controls (bottom
panels). The CA1 region is shown.
(D) Proliferating cell nuclear antigen (PCNA), a proliferation/S phase marker, is induced in p25-expressing neurons in CK-p25 brains (top panels), but not in
neurons of WT controls (bottom panels). The CA1 region is shown.
(E) p25-expressing neurons in CK-p25 brains are not immunoreactive for the mitotic marker phosphoserine 10 histone H3 (pH3) (top panels). Subventricular zone
(SVZ) of the same CK-p25 brain is shown as a positive control for mitotic cells that display phosphohistone H3 immunoreactivity.
Scale bars = 50 mm.Double-Strand DNA Damage and Cell-Cycle Activity
Are Tightly Associated and Precede Neuronal Death
Costaining with gH2AX and Ki-67 in CK-p25 mice revealed that
neurons undergoing aberrant expression of cell-cycle proteins
also exhibited double-strand DNA breaks, and vice versa, at
high concurrency (92.3% ± 2.7% SD), suggesting that the two
events are tightly linked (Figure 3A). In CK-p25 mice induced for
8 weeks (a period when massive neurodegeneration is evident
[Cruz et al., 2003]), the DNA damage marker gH2AX and the
cell-cycle progression marker Ki-67 were each associated with
pyknotic nuclei (Figure 3B). Over 70% of CA1 neurons in
CK-p25 mice that were positive for both p25-GFP and gH2AX
or both p25-GFP and Ki-67 had pyknotic nuclei, compared to
only 34% of neurons positive for p25-GFP alone (Figure 3B). Ex-
periments in cultured neurons (Figure S2) and in vivo (Cruz et al.,
2003) indicate that p25-expressing neurons die primarily through
apoptosis as indicated by immunoreactivity to cleaved caspase-
3 and cleaved PARP1. Interestingly, in CK-p25 mice subjected to
p25 expression for 2 weeks followed by suppression of p25 ex-
pression for 4 weeks (by feeding a doxycycline diet), we observed
that gH2AX signal was abrogated (Figure 3C), while no signs of
neuronal loss were observed (Fischer et al., 2005). This indicates
that the degree of gH2AX formation observed after 2 weeks is
reversible, and that gH2AX formation in CK-p25 mice precedes
and is not secondary to cell death. Furthermore, we observed
that the pan-caspase inhibitor z-VAD-fmk had no effect on
p25-mediated gH2AX formation, further excluding DNA damage
as a downstream consequence of apoptotic events (Figure S3).806 Neuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc.
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damage events are tightly correlated with each other, and that
they precede cell death in neurons with p25 accumulation.
p25 Interacts with and Inhibits HDAC1
The tight association of cell-cycle protein expression and DNA
damage in CK-p25 mice suggested that a common mechanism
might underlie these events. As both gene transcription and
susceptibility to DNA damage are known to be tightly linked to
the chromatin state, we considered the involvement of HDACs
in the induction of aberrant neuronal cell-cycle expression and
DNA damage by p25/Cdk5. Inhibition of HDACs can induce
gene transcription and also increase sensitivity of DNA to
DNA-damaging agents, both through increased accessibility
(Cerna et al., 2006).
Of particular interest was HDAC1, based on its reported role in
transcriptional repression of cell-cycle-related genes such as
p21/WAF, cyclins A, D, and E, and cdc25A (Brehm et al., 1998;
Lagger et al., 2002; Stiegler et al., 1998). We determined that in
forebrains of CK-p25 mice induced for 2 weeks, p25 interacted
with HDAC1 in vivo (Figure 4A). Interaction with HDAC1 was
observed with both p25 and p35 cotransfected in 293T cells
(Figure 4B). Interestingly, HDAC1 had a >12-fold higher degree
of interaction with p25 compared to the physiological, non-
cleaved p35 (Figure 4B), which does not exert neurotoxicity.
The preferential binding of HDAC1 with the pathological mole-
cule p25 raised the interesting possibility that the p25/HDAC1
interaction may have deleterious consequences.
Because HDAC1 is exclusively localized in the nucleus (de
Ruijter et al., 2003), we examined the localization of p25-GFP
in the CK-p25 mouse (Figure S4). While abundant p25-GFP
signal was observed in the cytoplasm, a lower but significant nu-
clear pool of p25-GFP was also observed, providing a basis for
p25/HDAC1 interaction. This is consistent with previous reports
of nuclear localization of p35 or p25 (O’Hare et al., 2005).
We further characterized the p25/HDAC1 interaction by iden-
tifying the interaction domains. To this end, we generated multi-
ple HDAC1 fragments spanning the entire protein, the C-terminal
region, the N-terminal region containing the catalytic domain, or
a small N-terminal region within the catalytic domain. By exam-
ining the ability of these fragments to coimmunoprecipitate with
full-length p25, we mapped the interaction domain of p25 and
Figure 2. Double-Strand DNA Damage Occurs
Following p25 Induction
(A) Western blots from induced CK-p25 mouse forebrain
lysates show increased levels of gH2AX and Rad51 compared
to WT controls. Asterisk indicates nonspecific band. Quantifi-
cation of gH2AX levels from multiple WT controls (n = 5) and
CK-p25 mice (n = 5) induced between 2 and 12 weeks are
shown in the top panel.
(B) Staining of vibratome sections with gH2AX reveals immu-
noreactivity specifically in the nuclei of p25-GFP-expressing
neurons in 2-week-induced CK-p25 mice (top panels), but
not in neurons of WT controls (bottom panels). The CA1 region
is shown. Inset is a magnification of gH2AX signal showing
punctate nuclear staining.
(C) Primary cortical neurons were infected with increasing
titers of herpesvirus expressing p25 (p25-HSV) or lacZ-HSV
control and analyzed for gH2AX levels by western blot.
(D) Primary cortical neurons infected with p25-HSV and fixed 8
hr postinfection display robust immunoreactivity with gH2AX
(right panels) compared to control uninfected neurons (left
panels). p25 overexpression was verified with p35 antibody
(top panels). Top and bottom panels are from different fields.
Scale bar in (B) and (D) = 50 mm.
(E) Comet assays were carried out on primary neurons in-
fected with p25-HSV or lacZ-HSV for 10 hr. Representative
micrographs of comet assay fields are shown in the left and
middle panels for p25-HSV-infected and lacZ-HSV-infected
neurons, respectively. Comet tails indicate DNA with breaks,
resulting in increased migration toward the direction of the
current (left to right). Right panel shows quantification of the
percentage of neurons with comet tails from three separate
experiments. Results are displayed as fold change versus
control (lacZ-HSV-infected) neurons. p values (**p < 0.005)
were calculated from multiple experiments by two-tailed, un-
paired Student’s t test. Averages from multiple experiments
± SD are shown in (A) and (E).Neuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc. 807
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catalytic domain (Figure 4C).
The interaction of p25 with the catalytic domain of HDAC1
suggested that p25/Cdk5 may affect the enzymatic activity and/
or the function of HDAC1. Indeed, overexpression of p25 and
Cdk5 in 293T cells resulted in a significant decrease in endoge-
nous HDAC1 activity (Figure 4D). Importantly, inhibitory effects
on endogenous HDAC1 activity were confirmed in vivo in hippo-
campi from 2-week-induced CK-p25 mice compared to WT con-
trols (Figure 4D). Similar effects on HDAC1 activity were observed
in primary neurons infected with p25-HSV (data not shown). To
determine whether this was linked to increased HDAC1 repressor
activity, we coexpressed p25 and Cdk5 with HDAC1-Gal4 in a
luciferase reporter system. Fusion of HDAC1 with Gal4 signifi-
cantly repressed Gal4 transcriptional activity (Nagy et al., 1997)
(Figure 4E, compare columns 2 and 1); however, coexpression
with p25 increased HDAC1-Gal4-induced reporter activity
7.9-fold, indicating decreased repression by HDAC1 (column 3).
Importantly, this effect was not observed with p35/Cdk5 or with
p25/dominant-negative Cdk5 (columns 4 and 5), indicating that
the inhibitory effect on HDAC1 transcriptional repression is
specific to p25 and not p35 and that it requires Cdk5 activity.
Inhibition of HDAC catalytic activity results in the loss of HDAC1
association with thep21/WAF1promoter region (Gui et al., 2004).
Therefore, we investigated whether p25/Cdk5 could inhibit the
association of HDAC1 with the promoter of p21/WAF1 and other
cell-cycle-related genes. First, we examined whether overex-
pression of p25 could affect the overall chromatin association
of HDAC1 in primary neurons. We observed that HSV-mediated
overexpression of p25 led to a decrease in chromatin-bound
HDAC1 and an increase in the nucleoplasmic, non-chromatin-
bound fraction of HDAC1 (Figure 4F). Next, we carried out
HDAC1 chromatin immunoprecipitation experiments in 293T
cells transfected with p25/Cdk5 or a vector control to examine
the association of HDAC1 with the core promoter regions of
p21/WAF1 and E2F1. Overexpression of p25/Cdk5 resulted in
a loss of HDAC1 association with p21/WAF1 and E2F1 pro-
moters, as well as a concomitant increase in associated histone
acetylation, suggesting a loss of histone deacetylation in this
locus (Figure 4G). As HDAC1 association and local histone
Figure 3. Double-Strand DNA Breaks and Aberrant
Cell-Cycle Activity Are Concomitant and Precede
Neuronal Death
(A) Double immunofluorescence staining for Ki-67 (green) and
gH2AX (red) carried out in 2-week-induced CK-p25 mice re-
vealed that cell-cycle activity and double-strand DNA breaks
occur concurrently. Representative images of the CA1 region
are shown in the left panels, and quantification of neurons
immunoreactive for both gH2AX and Ki-67, gH2AX only, or
Ki-67 only from multiple 2-week-induced CK-p25 mice are
shown in the histogram at right. a: gH2AX + Ki-67 versus
gH2AX only, p < 0.001; b: gH2AX + Ki-67 versus Ki-67 only,
p < 0.001. One-way ANOVA with Neuman-Keuls multiple
comparison test was used to calculate p values.
(B) gH2AX and Ki-67 are closely associated with dying neu-
rons at 8 weeks of p25 induction. Representative images
showing association of gH2AX and Ki-67 with pyknotic nuclei
are shown in the first, second, and third panels. The fourth
panel shows a magnification of the boxed region in third panel.
Quantification of cell death (pyknotic nuclei) in p25-GFP- and
gH2AX-immunoreactive neurons, p25-GFP- and Ki-67-immu-
noreactive neurons, and neurons immunoreactive for
p25-GFP but not gH2AX or Ki-67 is shown from multiple
2-week- and 8-week-induced CK-p25 mice. a: p25 only ver-
sus p25 + gH2AX, p < 0.01; b: p25 only versus p25 + Ki-67,
p < 0.01. One-way ANOVA with Neuman-Keuls multiple com-
parison test was used to calculate p values. Averages from
multiple experiments ± SD are shown in (A) and (B).
(C) CK-p25 mice were induced for 2 weeks (top panels) and
sacrificed or were induced for 2 weeks followed by 4 weeks
of suppression by doxycycline diet prior to sacrifice. Sections
were examined for GFP and gH2AX signals. It was previously
determined that 2 weeks of induction of p25 followed by
4 weeks of suppression does not result in neuronal loss
(Fischer et al., 2005).
Scale bars = 100 mm.808 Neuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc.
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(A) Forebrains from 2-week-induced CK-p25 and WT control mice were homogenized, and lysates were immunoprecipitated with HDAC1 antibody as described
and probed for p25-GFP and HDAC1.
(B) FLAG-tagged HDAC1 was overexpressed with p25-GFP or p35-GFP in HEK293T cells, immunoprecipitated with FLAG-conjugated beads as described, and
probed for p25-GFP or p35-GFP.
(C) FLAG-tagged full-length HDAC1 or various truncation mutations were overexpressed with p25-GFP and immunoprecipitated with FLAG-conjugated beads as
described. The catalytic domain is indicated in red-brown.
(D) Left panel: HEK293T cells were transfected with vector or p25/Cdk5. Fifteen hours later, endogenous HDAC1 was immunoprecipitated and assayed for
histone deacetylase activity as described. Averages from multiple experiments are displayed as fold change versus control (vector only). Right panel: hippocampi
from 2-week-induced WT and CK-p25 mice were dissected and assayed for endogenous HDAC1 activity as described. p values (**p < 0.005, *p < 0.05) were
calculated from multiple experiments by two-tailed, unpaired Student’s t test.
(E) p25/Cdk5 inhibits the transcriptional repressor activity of HDAC1. HDAC1-Gal4 construct was cotransfected with blank vector or p25/Cdk5 and then
measured for luciferase reporter activity as described. Values were normalized to protein levels of Gal4 constructs and are expressed as relative light units
(RLU) (HDAC1-Gal4 only = 1).
(F) Primary cortical neurons were infected with GFP-HSV or p25-HSV and then subjected to fractionation as described. Lamin A and histone H3 were used as
markers for the nuclear and chromatin fractions, respectively. Band densitometry quantifications are shown in the histogram on the right. Averages from multiple
experiments ± SD are shown in (D)–(F).
(G) HEK293T cells were transfected with blank vector or p25 and Cdk5, crosslinked, and subjected to chromatin immunoprecipitation using HDAC1 or histone H3
acetylated at lysine 9 (aH3K9) antibody. Immunocomplexes were subjected to semiquantitative PCR amplification using primers toward the core promoter
regions of E2F1 and p21/WAF.deacetylation of specific promoter regions are linked with their
repression, this result suggested that p25/Cdk5-mediated loss
of HDAC1 activity and association with promoters of cell-cycle-
related genes may account for the aberrant expression of cell-
cycle-related genes observed in the CK-p25 mice.
Collectively, our results demonstrate that p25/Cdk5 inhibits
multiple facets of HDAC1 function, including histone deacetylase
activity, transcriptional repressor activity, and association with
chromatin and specific promoter regions.
Inhibition of HDAC1 Induces DNA Damage, Cell-Cycle
Activity, and Death
Our findings raised the possibility that p25/Cdk5 might cause
both cell-cycle activity and DNA damage through inhibition ofNeuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc. 809
Neuron
Deregulation of HDAC1 by p25/Cdk5 in NeurotoxicityHDAC1 activity. We examined the effects of siRNA-mediated
knockdown and pharmacological inhibition of HDAC1. Knock-
down of HDAC1 with a previously published sequence (see
Supplemental Experimental Procedures) resulted in a significant
increase in double-strand DNA breaks and cell death compared
to the random sequence control (Figure 5A). In addition, treat-
ment of primary neurons with a 1 mM concentration of the class
I HDAC inhibitor MS-275, which results in >70% inhibition of
HDAC1 activity with lesser effects on HDAC3 and HDAC8 (Hu
et al., 2003), was sufficient to increase double-strand DNA breaks
(8.1-fold increase) and stimulate the aberrant expression of Ki-67
(1.8-fold increase) compared to controls (Figure 5B). These re-
sults demonstrate that inhibition of HDAC1 in neurons can induce
double-strand DNA breaks and cell-cycle activity in neurons.
Figure 5. Loss of HDAC1 or Pharmacological Inhibi-
tion of HDAC1 Results in DNA Damage, Cell-Cycle
Activity, and Neurotoxicity
(A and B) Primary cortical neurons were transfected with either
HDAC1 siRNA or random sequence siRNA along with GFP at
a 7:1 ratio to label transfected neurons. Cells were fixed at
24 hr, 48 hr, and 72 hr posttransfection and immunostained
for gH2AX. GFP-positive neurons were scored for gH2AX im-
munoreactivity and for cell death based on nuclear condensa-
tion and neuritic integrity as described.
(A) Left: representative micrographs. HDAC1 siRNA or control
(random sequence) siRNA-transfected neurons are indicated
by arrows. The HDAC1 siRNA-transfected neurons display
neuritic breakage. The inset is a magnification of the gH2AX
staining of the neuron indicated by the rightmost arrow in
the lower left panel, showing gH2AX foci of varying sizes.
Right: percentages of gH2AX and cell death. It was noted
that transfection of control siRNA per se appeared to cause
a low but significant baseline level of gH2AX immunoreactivity
and cell death.
(B) Primary cortical neurons were treated with a 1 mM concen-
tration of the HDAC1 inhibitor MS-275 for 24 hr, fixed, and
immunostained for gH2AX and Ki-67. Controls were treated
with equal amounts of vehicle (DMSO). Total numbers of
gH2AX- and Ki-67-positive neurons were quantified over
20 microscope fields (field diameter  900 mm). Averages
from multiple experiments ± SD are shown in (A) and (B).
(C) Wild-type mice were injected intraperitoneally with 50 mg/
kg MS-275 (n = 3) or saline (n = 3) daily for 10 days and then
sacrificed and examined for gH2AX. MS-275 injection resulted
in a dramatic induction of gH2AX within the CA1 (bottom
panels), whereas saline injection did not induce gH2AX (top
panels).
Scale bars = 100 mm.
Furthermore, daily intraperitoneal injection of
a high dose of MS-275 (50 mg/kg) for 10 days in
WT mice resulted in a dramatic induction of
gH2AX in CA1 neurons (Figure 5C) as well as other
brain regions (Figure S5), a result that was not ob-
served with saline injection. In contrast to previous
studies using the nonselective HDAC inhibitors
sodium butyrate and trichostatin A (Fischer et al.,
2007; Levenson et al., 2004), MS-275 also impaired
associative learning capability in WT mice in a
dose-dependent manner, as assessed using a
contextual fear conditioning paradigm (Figure S6). These results
support that loss of HDAC1 activity can cause DNA damage,
neurodegeneration, and neurologic defects in vivo.
HDAC1 Gain of Function Rescues against DNA Damage
and Neuronal Death in Cultured Neurons and In Vivo
Having demonstrated that inhibition of HDAC1 induces double-
strand DNA breaks and aberrant cell-cycle activity, we examined
whether HDAC1 gain of function by overexpression can attenu-
ate p25-mediated DNA damage and neurotoxicity. To this end,
we overexpressed HDAC1 or control constructs followed by viral
expression of p25 at a high rate of infection (>80%). Overexpres-
sion of HDAC1, but not HDAC2, decreased the percentage of
neurons positive for p25-induced gH2AX by 37.9% compared810 Neuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc.
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sion of HDAC1 could rescue against cell death induced by
transfection with p25-GFP. Coexpression of HDAC1, but not
a catalytically dead mutant (HDAC1 H141A), rescued against
p25-mediated neuronal death by 59.8% compared to the control
(Figure 6B). Similar results were obtained when examining apo-
ptosis as determined by cleaved caspase-3 immunoreactivity
(Figure S7). These results demonstrate that restoring HDAC1 ac-
tivity can rescue against p25-mediated DNA damage and death.
Interestingly, treatment with the histone acetyltransferase
(HAT) inhibitor garcinol also rescued against p25-mediated
neurotoxicity (Figure S7). However, coexpression of HDAC1
plus garcinol treatment did not have any additional protective
benefit compared to HDAC1 coexpression or garcinol treatment
alone (Figure S7), suggesting that HDAC1 neuroprotection
involves deacetylation of histones.
Next, we sought to examine whether the neuroprotective prop-
erties of HDAC1 could be recapitulated in an established in vivo
model for stroke, i.e., ratssubjected to transient forebrain ischemia.
We and other groups have previously demonstrated the involve-
ment of p25 in this model (Garcia-Bonilla et al., 2006; Wang et al.,
2003; Wen et al., 2007). Also, p25 is upregulated in human post-
mortem brains following ischemic stroke (Mitsios et al., 2007). Fur-
thermore, cell-cycle markers such as cyclin A, PCNA, and E2F1,
which were upregulated in our p25 mice (Figure 1), are upregulated
in rodent models for stroke/ischemia (Rashidian et al., 2007).
Therefore, we examined whether gH2AX levels are upregu-
lated in this model as well. Brains from rats subjected to unilateral
transient forebrain ischemia for various periods were examined
forgH2AX immunoreactivity. Increased gH2AX immunoreactivity
was observed as early as 3 hr postischemia in the ischemic region
(Figure 6C). Significant levels of gH2AX were not observed in the
ipsilateral nonischemic region (data not shown) or the contralat-
eral hemisphere (Figure 6C).
We examined whether overexpression of HDAC1 conferred
neuroprotection in this model. To this end, Sprague-Dawley
rats were injected with saline, blank HSV, HSV-HDAC1, or HSV-
HDAC1 H141A catalytically dead mutant into the striatum, which
resulted in robust neuronal expression of constructs (Figure 6D).
After 24 hr, rats were subjected to bilateral transient forebrain is-
chemia. Six days later, brain sections were stained with gH2AX
and fluoro-jade to label degenerating neurons. We and other
groups have observed that fluoro-jade labels regions undergoing
apoptotic neuronal death (Figure S8) (Zuch et al., 2000).
HSV-mediated overexpression of HDAC1 in the striatum re-
sulted in a 38% reduction in gH2AX-positive neurons in the stria-
tum compared to blank HSV, while the HDAC1 H141A mutant
did not confer neuroprotection (Figures 6E and 6F). In addition,
the number of degenerating neurons as labeled by fluoro-jade
decreased significantly (33%) following HDAC1 expression (Fig-
ures 6E and 6G). Importantly, this demonstrates that increasing
HDAC1 activity can protect neurons against ischemia-induced
DNA damage and neurotoxicity in vivo.
DISCUSSION
The CK-p25 mouse is a model for neurodegeneration in which
neurons predictably begin to die at around 5–6 weeks of induc-
tion (Cruz et al., 2003; Fischer et al., 2005). In our current study,
using an unbiased approach of examining the gene expression
profile at a specific time point of induction followed by validation,
we determined that aberrant expression of cell-cycle proteins
and induction of double-strand DNA breaks are early events in
p25-mediated neurodegeneration. Furthermore, we identified
deregulation of HDAC1 activity as a mechanism involved in
p25-mediated double-strand DNA break formation, cell-cycle
protein expression, and neuronal death. Collectively, our results
outline a pathway in neurodegeneration by which the inactivation
of HDAC1 by p25 leads to enhanced susceptibility of DNA to dou-
ble-strand breaks and the derepression of transcription, leading
to aberrant expression of cell-cycle-related genes. In addition,
our findings provide mechanistic insights into a common link
between DNA damage and aberrant cell-cycle activity in neuro-
degeneration. As cell-cycle activity, DNA damage, and p25 accu-
mulation are emerging as important pathological components of
various neurodegenerative conditions, this pathway may consti-
tute a shared mechanism responsible for neuronal death in mul-
tiple conditions such as stroke/ischemia, AD, and Parkinson’s
disease (PD). The neurotoxic effects of p25 accumulation and
downstream events appear to be reversible (Figure 3C), further
advocating the therapeutic potential of targeting this pathway
in conditions involving neuronal death. Our proposed pathway
is summarized in Figure 7. It will be of interest to examine the
protective properties of HDAC1 gain of function in various mouse
models of neurodegenerative diseases such as amyotrophic
lateral sclerosis, AD, and PD in future studies.
HDAC1 Inactivation by p25/Cdk5
We have demonstrated that p25 can inhibit multiple aspects of
HDAC1 activity, including HDAC1 catalytic activity and associa-
tion of HDAC1 with chromatin. This inhibition appears to be Cdk5
dependent (Figure 4E). How does p25/Cdk5 inhibit HDAC1? This
may involve the posttranslational modification of HDAC1 by p25/
Cdk5. HDAC1 catalytic activity and association with corepres-
sors can be modulated by phosphorylation (Galasinski et al.,
2002; Pflum et al., 2001). Alternatively, the p25/HDAC1 interac-
tion may recruit p25/Cdk5 to HDAC1-containing corepressor
complexes, where p25/Cdk5 phosphorylates and modulates
corepressors required for HDAC1 activity, such as mSin3a or
SMRT/NcoR2 (de Ruijter et al., 2003; Nagy et al., 1997).
HDAC1 Inactivation and Cell-Cycle Activity
While aberrant cell-cycle activity in neurons in neurodegenerative
states has been extensively documented, the underlying mecha-
nisms and purposes are unclear. Our model introduces loss of
HDAC1 activity as an underlying mechanism and suggests a
simplified model of aberrant cell-cycle activity as a pathological
derepression of multiple cell-cycle genes that are normally
suppressed in neurons. p25/Cdk5 inhibited the transcriptional
repression activity of HDAC1 in a luciferase reporter system
(Figure 4E) and induced the disassociation of HDAC1 from the
promoter region of the cell-cycle proteins E2F1 and p21/WAF
(Figure 4G). Inhibition of HDAC1 in primary neurons resulted in
upregulation of the cell-cycle activity marker Ki-67 (Figure 5B).
Thus, our model suggests that constitutive HDAC1, which is
normally associated with and represses cell-cycle-related genesNeuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc. 811
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(A) Overexpression of HDAC1 rescues against p25-mediated formation of gH2AX. Primary cortical neurons were transfected with vector, HDAC1, or HDAC2 as
described. At 12 hr posttransfection, neurons were infected with p25-HSV virus, fixed after 8 hr, and immunostained for gH2AX. HDAC-positive cells were scored
for immunoreactivity toward gH2AX. Scale bar = 50 mm.
(B) Overexpression of HDAC1 rescues against p25-mediated neurotoxicity. Primary cortical neurons were transfected with p25-GFP plus blank vector, FLAG-
HDAC1, or catalytically dead FLAG-HDAC1 H141A mutant. At 24 hr posttransfection, cells were fixed and immunostained for FLAG. p25-transfected cells and
p25/HDAC1-transfected cells were scored for cell death based on nuclear condensation and neuritic integrity as described. For (A) and (B), averages from
multiple experiments ± SD are shown. Representative micrographs for HDAC1 are shown in the left panels. Arrows indicate p25-positive neurons expressing
or not expressing HDAC1. p values (**p < 0.005 for HDAC1 versus control) were calculated from multiple experiments by two-tailed, unpaired Student’s t test.
(C) Adult Sprague-Dawley rats were subjected to unilateral middle cerebral artery occlusion (MCAO) as described. Paraffin sections from brains fixed at 3 hr post
MCAO show gH2AX immunoreactivity specifically within the ischemic area (left panels), but not in the contralateral area (right panels). Images are representative
of multiple animals. Average numbers of gH2AX-positive cells per field (field diameter  900 mm) from multiple experiments ± SD are displayed. Twenty fields
were counted per experiment. p values (**p < 0.005) were calculated from multiple experiments by two-tailed, unpaired Student’s t test. Scale bar = 50 mm.
(D) Injection of blank vector expressing GFP into striatum results in efficient and widespread expression in striatal neurons. Injection of virus into the striatum of
adult Sprague-Dawley rats was followed by examination of GFP expression after 24 hr. Scale bar = 100 mm in left panel, 30 mm in right panel.
(E) HDAC1 expression protects against ischemia-induced neuronal death and gH2AX formation in vivo. Adult Sprague-Dawley rats were injected with virus in the
striatum, subjected to bilateral transient forebrain ischemia after 24 hr, and examined 6 days later for fluoro-jade and gH2AX staining as described. Represen-
tative images from mice injected with HSV-HDAC1, HSV-HDAC1 H141A, and blank HSV (vector) are shown. Scale bars = 100 mm.
(F) Quantification of gH2AX-positive cells from mice injected with saline, HSV-HDAC1, HSV-HDAC1 H141A, or vector (blank) and mice subjected to sham
procedure.
(G) Quantification of fluoro-jade-positive cells from the mice in (F). For (F) and (G), Data are presented as mean ± SEM. p values (*p < 0.05, **p < 0.005) were
calculated from multiple experiments by two-tailed, unpaired Student’s t test.812 Neuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc.
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expression of cell-cycle genes. The idea that aberrant cell-cycle
gene expression in neurons is a consequence of loss of HDAC1
repressional activity is consistent with the previously reported
roles of HDAC1 as a transcriptional repressor for many cell-cycle
genes. DNA damage induced by HDAC1 inactivation may also
play a role in aberrant cell-cycle activity, as it has been demon-
strated that increased oxidative DNA damage in the ‘‘harlequin’’
mouse mutants or drug-induced DNA damage in primary neu-
rons can induce aberrant cell-cycle activity (Klein et al., 2002;
Kruman et al., 2004).
HDAC1 Inactivation and DNA Damage
Double-strand DNA breaks also preceded neuronal death in our
p25 model. Future studies should address specifically how
HDAC1 inactivation results in double-strand DNA damage and
cell-cycle activity. One likely scenario involves hypersensitiza-
tion of chromatin to DNA-damaging agents following loss of
HDAC1 activity. In cancer cells, HDAC inhibitors can hypersen-
sitize DNA to damaging agents such as ultraviolet and g irradia-
tion by increasing the acetylation state and thus the accessibility
of chromatin (Cerna et al., 2006).
Interestingly, overexpression of p25 or HDAC1 inhibition/
knockdown was sufficient to induce DNA damage in neurons
and did not require additional genotoxic stimuli. Neurons are
constantly subjected to DNA-damaging events; for example, it
has been estimated that the typical neuron of an aged mouse
is subjected to 2 million oxidative lesions per day (Hamilton
et al., 2001). Therefore, enhanced accessibility to DNA-damag-
ing agents, combined with the relatively low levels of DNA repair
factors present in neurons compared to proliferating cells (Gob-
bel et al., 1998; Nouspikel and Hanawalt, 2003), may result in
a robust accumulation of DNA damage.
DNA Damage, Cell-Cycle Activity, and Cell Death
In this study, we report the formation of double-strand DNA
breaks in the CK-p25 model as well as in a rodent model for
stroke/ischemia. Both double-strand DNA breaks and cell-cycle
activity preceded and were later tightly associated with neurode-
generation (Figure 3B). Compared to single-nucleotide lesions
such as 8-oxoguanine lesions, double-strand DNA breaks are
potentially lethal lesions that induce cell-cycle-dependent
checkpoint responses in proliferating cells, resulting in cell death
(Sancar et al., 2004). However, because neurons are postmitotic,
DNA damage events per se may have only limited toxic conse-
quences, with the exception of altered gene expression (Nouspi-
kel and Hanawalt, 2003). Thus, double-strand DNA breaks and
cell-cycle events such as DNA replication may synergistically
induce cell death in CK-p25 neurons, likely in a checkpoint-
dependent manner. In support of this notion, the p53 DNA
damage checkpoint protein is upregulated in CK-p25 mice,
and knockdown of p53 results in reduction of neuronal death in
p25-transfected neurons (Kim et al., 2007).
Role for HDAC1 in Postmitotic Neurons
As an important modulator of transcription, HDAC1 is undoubt-
edly involved in a variety of biological processes, and its in-
volvement is well established in the regulation of the cell cycle
in proliferating cells. Studies in the developing zebrafish retina
demonstrate a role for HDAC1 in cell-cycle exit and differenti-
ation of retinal progenitors into neurons (Yamaguchi et al.,
2005). Our study implicates HDAC1 in the maintenance and
survival of adult neurons as well. Our findings suggest a func-
tion for HDAC1 in maintaining a state of ‘‘quiescence’’ through
transcriptional repression of cell-cycle genes. We also demon-
strate a role for HDAC1 in maintaining DNA integrity in adult
neurons, a function that may be tightly linked to its regulation
of the accessibility of DNA to damaging agents. Collectively,
our results outline an important role within the CNS for
HDAC1, the deregulation of which can lead to aberrant expres-
sion of cell-cycle genes, DNA damage, and ultimately death in
adult neurons.
Figure 7. Schematic Model
Proposed model for p25-mediated cell death involving inhibition of HDAC1
activity, which leads to double-strand DNA breaks and aberrant cell-cycle
activity. Neurotoxic stimuli such as ischemia result in p25 accumulation. This
accumulation results in interaction with and inhibition of multiple aspects of
HDAC1 activity, as shown in Figure 4, in a manner that is dependent on
Cdk5, as shown in Figure 4E. Inhibition of HDAC1 results in DNA damage
and aberrant expression of cell-cycle genes, which is likely associated with lo-
cal histone deacetylation (Figure 4G; Figure 5; Figure S7) and which ultimately
leads to neuronal death (Figure 3). The neurotoxic effects of p25 accumulation
and downstream effects appear to be reversible before a certain period of
induction (Figure 3C). Circles labeled ‘‘N’’ represents nucleosomes; ‘‘A’’ repre-
sents acetylation of histone tails. The nucleosomes with ‘‘A’’ represent acety-
lated nucleosomes and open chromatin loci, while the nucleosome at the far
right represents a deacetylated nucleosome and closed chromatin locus.Neuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc. 813
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We have shown that inhibition of HDAC1 can lead to DNA dam-
age, cell-cycle gene expression, and neuronal death. In support
of this idea, recent studies reporting the neuroprotective function
of p130 and histone deacetylase-related protein (HDRP) have
demonstrated a requirement for association with HDAC1 for
these proteins’ prosurvival effects (Liu et al., 2005; Morrison
et al., 2006). Furthermore, a recent phase I clinical trial of
MS-275 in leukemia patients demonstrated neurologic toxicity
manifesting as unsteady gait and somnolence as a dose-limiting
toxicity (DLT) (Gojo et al., 2006). In addition, numerous studies
have demonstrated neurotoxic effects of high-dose general
HDAC inhibitor treatment (Boutillier et al., 2002, 2003; Kim
et al., 2004; Salminen et al., 1998).
On the other hand, it is clear that HDAC inhibitors can have ben-
eficial effects. We recently demonstrated that treatment with the
nonselective HDAC inhibitor sodium butyrate enhances synapse
formation and long-term memory recall (Fischer et al., 2007), and
learning and memory benefits have been reported with trichosta-
tin A (Levenson et al., 2004; Vecsey et al., 2007). Along similar
lines, studies have shown beneficial effects of HDAC inhibitors
in patients or models of psychiatric disorders such as depression
(Citrome, 2003; Tsankova et al., 2006). In addition, HDAC inhibi-
tors such as phenylbutyrate have neuroprotective properties,
within a therapeutic window, in models of Huntington’s disease
(HD) (Hockly et al., 2003; Langley et al., 2005; McCampbell
et al., 2001; Steffan et al., 2001). The use of HDAC inhibitors in
HD models is based on the finding that huntingtin inhibits the
HATs CREB-binding protein (CBP) and p300/CBP-associated
factor (P/CAF), leading to a deficiency in levels of histone acety-
lation (Bates, 2001).
Thus, both beneficial and adverse signals can be triggered by
histone deacetylase inhibition. These effects are likely based on
discrepancy in functions and gene targets of the different HDACs.
For example, it was recently shown that specific downregulation
of the class II HDACs HDAC4 and HDAC5 by the antidepressant
imipramine derepresses BDNF expression and suppresses de-
pression-like behavior (Tsankova et al., 2006). Thus, inhibition
of other HDACs may result in benefits through derepression of
beneficial gene expression, while HDAC1 inhibition elicits delete-
rious consequences such as derepression of cell-cycle genes.
We are currently in the process of elucidating the discrepancies
in function and gene targets of the different HDACs that may
account for the varying effects of HDAC inhibition.
Also, we cannot overlook the possibility that the beneficial
versus deleterious effects of HDAC inhibition may also depend
closely on the dosage and length of HDAC inhibition, as well as
the context (e.g., state of hypoacetylation inHuntington’sdisease).
Our current study demonstrates the therapeutic potential for
replenishing HDAC1 activity in certain neurodegenerative con-
texts such as ischemia (Figure 6). Previous studies with general
HDAC inhibitors and our current study collectively illustrate the
complex and broadly impacting nature of manipulating HDAC
activity and underline the importance of chromatin regulation in
a variety of processes in the CNS. Importantly, our study exem-
plifies the catastrophic consequences of deregulating this
process and introduces an unexpected avenue for therapeutic
strategies in neurodegeneration.
EXPERIMENTAL PROCEDURES
A detailed description of all procedures is included in the Supplemental Exper-
imental Procedures.
Mice
CK-p25 double-transgenic mice were raised on a doxycycline-containing diet
and then switched to a normal diet at 6–8 weeks of age to induce p25-GFP in
a postnatal, forebrain neuron-specific manner as described previously (Cruz
et al., 2003). Further details are provided in Supplemental Experimental
Procedures.
Microarray Analyses
Total RNA was extracted from forebrains of 2-week-induced CK-p25 trans-
genic mice (n = 3) and uninduced CK-p25 controls (n = 3) using TRIzol reagent
(Sigma). RNA was subjected to further purification with RNeasy columns
(QIAGEN), reverse transcribed, biotin labeled, and hybridized onto Mouse
Genome 430A 2.0 arrays (Affymetrix). Array data was analyzed using dCHIP
and GeneChip Operating Software (GCOS, Affymetrix) as described in Supple-
mental Experimental Procedures.
Quantitative RT-PCR Analyses
Hippocampi from 2-week-induced CK-p25 mice and WT controls were incu-
bated in RNAlater solution (Ambion). Total RNA was isolated using TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions. Reverse
transcription of equal amounts of total RNA was carried out using a SuperScript
III First-Strand Synthesis kit (Invitrogen) according to the manufacturer’s
instructions. Semiquantitative conditions were obtained for all primers with
sequence and cycle information provided in Supplemental Experimental
Procedures. Band quantifications were normalized to those obtained for actin
for each animal.
Comet Assay
Primary rat cortical neurons at 6–8 days in vitro (DIV) were infected with
herpesvirus expressing p25 (p25-HSV) or lacZ (lacZ-HSV). After 10 hr, neurons
were dissociated and embedded in a thin layer of agarose. Lysis, alkaline treat-
ment, and single-cell gel electrophoresis (comet assay) were carried out.
Immunohistochemistry
Mice were transcardially perfused, and brains were prepared as paraffin sec-
tions or free-floating vibratome sections. Citrate buffer-based antigen retrieval
was required for paraffin sections. Primary antibodies used with paraffin sec-
tions were gH2AX (monoclonal from Upstate, polyclonal from Trevigen), Ki-67
(Novocastra), PCNA (Oncogene Sciences), phosphoserine 10 histone H3
(Upstate), and GFP (monoclonal from Santa Cruz, polyclonal from Molecular
Probes). Primary antibodies used with vibratome sections were GFP (Aves
Labs), gH2AX (Upstate), cleaved caspase-3 (Asp175, Cell Signaling Technol-
ogy), cleaved PARP1 (p25, Upstate), and NeuN (Chemicon). While the CA1
region of hippocampus is primarily shown in figures, similar results were
observed in the cortex as well (data not shown).
Immunoblot Analyses
CK-p25 and control forebrains were dissected and Dounce homogenized in
RIPA buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% NP40, 0.5% sodium de-
oxycholate, 0.1% SDS) containing protease and phosphatase inhibitors. Equal
quantities of brain lysates were subjected to SDS-PAGE and western blot anal-
ysis using antibodies to gH2AX (Trevigen), a-tubulin (Sigma), E2F1 (Santa
Cruz), cyclin A (Santa Cruz), p35 (Santa Cruz), p27 (Santa Cruz), GFAP (Sigma),
and bIII-tubulin (Sigma).
Luciferase Assays
HeLa cells were transfected with reporter, HDAC1-Gal4 fusion protein, and
either blank vector or p25 plus Cdk5 expression vectors. At 15 hr posttransfec-
tion, cells were lysed with passive lysis buffer and luciferase assay was per-
formed according to the manufacturer’s instructions (Promega). Values were
normalized to Gal4 protein levels, as renilla reporters were also substantially
repressed by HDAC1-Gal4.814 Neuron 60, 803–817, December 11, 2008 ª2008 Elsevier Inc.
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HEK293T cells were transfected, lysed, subjected to immunoprecipitation with
anti-FLAG-conjugated beads (Sigma), and analyzed by SDS-PAGE as
described in Supplemental Experimental Procedures. For in vivo analysis of
p25/HDAC1 interaction, 2-week-induced CK-p25 mice and WT control fore-
brains were Dounce homogenized in RIPA buffer, subjected to immunoprecip-
itation with anti-HDAC1 (Abcam), and analyzed as described in Supplemental
Experimental Procedures. Antibodies to HDAC1 (Abcam), GFP (Santa Cruz),
FLAG (Sigma), and p35/p25 (Sigma) were used for immunoblotting.
HDAC1 Enzymatic Activity Assay
HEK293T cells were transfected with blank vector or with p25 and Cdk5
expression vectors with Lipofectamine 2000. Cells were lysed with IP buffer
at 15 hr posttransfection and immunoprecipitated with anti-HDAC1 (Abcam).
Endogenous HDAC1 bound to beads was analyzed for histone deacetylase
activity using a histone deacetylase assay kit (Upstate) according to the man-
ufacturer’s instructions. Histone deacetylase activity was normalized to input
HDAC1 protein levels, which were analyzed by western blot. For analyses of
HDAC1 activity in vivo, hippocampi were dissected from 2-week-induced
CK-p25 mice and WT littermates and Dounce homogenized in IP buffer
with high salt (400 mM NaCl) to aid HDAC1 extraction. Lysates were immu-
noprecipitated (in IP buffer with final 200 mM NaCl) and analyzed as
described.
p25- and HDAC1-Based Toxicity Assays in Primary Neurons
Optimization of transfection conditions was required to minimize toxicity and
gH2AX induced by the transfection procedure itself, as described in Supple-
mental Experimental Procedures. For cell death rescue assays, primary
mouse cortical neurons were transfected with p25-GFP plus blank vector or
p25-GFP plus FLAG-HDAC1. At 24 hr posttransfection, neurons were fixed
and stained, and transfected neurons were scored for cell death based on
nuclear morphology and neuritic integrity or scored for immunoreactivity
toward cleaved caspase-3 (Cell Signaling Technology) in a blind manner.
Only cells with a level of transfection sufficient for the entire neuritic outline
to be clearly visible were counted. For gH2AX rescue assays, primary rat
cortical neurons were transfected with FLAG-HDAC1, FLAG-HDAC2, or
GFP and were infected with p25-HSV at 12 hr posttransfection. FLAG-
HDAC1-, FLAG-HDAC2-, or GFP-positive neurons were blindly scored for
gH2AX immunoreactivity.
Transient Forebrain Ischemia
For experiments examining HDAC1-mediated rescue of transient forebrain
ischemia, rats were subjected to bilateral transient forebrain ischemia as
described in Supplemental Experimental Procedures. Briefly, virus particles
were injected into the striatum of adult Sprague-Dawley rats. After 24 hr,
rats were subjected to ischemia by bilaterally occluding common carotid
arteries with aneurysm clips for 15 min, after which cerebral blood flow was
restored. After 6 days, mice were processed, subjected to gH2AX immunohis-
tochemistry, and subjected to fluoro-jade staining as described previously
(Wang et al., 2003). Histological quantification of gH2AX immunoreactivity
and fluoro-jade labeling in striatal neurons was carried out as described in
Supplemental Experimental Procedures. Averaged neuronal cell counts
were obtained from six animals per group.
For colabeling of fluoro-jade B with apoptosis markers, mice were subjected
to transient forebrain ischemia by middle cerebral artery occlusion as de-
scribed, except unilaterally with the contralateral hemisphere used as negative
control. Cleaved caspase-3 (Cell Signaling Technology) and cleaved PARP1
(Upstate) were used as apoptotic markers.
Subcellular Fractionation
Rat primary neurons at DIV 5–7 were infected with GFP-HSV or p25-GFP-HSV.
After 20 hr, neurons were subjected to chromatin fractionation as described in
Supplemental Experimental Procedures. Cytosolic/nuclear fractionation was
carried out using a nuclear extract kit (Active Motif) according to the manufac-
turer’s instructions. Antibodies to GFP (Sigma), HDAC1 (Abcam), and neurofi-
lament heavy subunit (Covance) were used for immunoblotting.
Chromatin Immunoprecipitation
For chromatin immunoprecipitation experiments, 293T cells were transfected
with the indicated constructs, fixed 14 hr after transfection with 1% formalde-
hyde, and processed according to the manufacturer’s instructions (#17-195,
Upstate). HDAC1 (ChIP grade, Abcam) and acetyl-H3K9 (Upstate) antibodies
were used to immunoprecipitate endogenous HDAC1 or histone H3 acetylated
at lysine 9, respectively. Core promoter regions of p21 and E2F1 were
amplified by PCR under semiquantitative conditions as described in the
Supplemental Experimental Procedures.
Fear Conditioning
Fear conditioning experiments were carried out as described previously
(Kim et al., 2007) using a fear conditioning apparatus (TSE Systems).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, eight figures, and two tables and can be found online at
http://www.neuron.org/supplemental/S0896-6273(08)00888-X.
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